Innovative Drug Development Solutions for Neurodegenerative Diseases
SeNostic is Revolutionising Neurodegenerative Disease Detection and Drug Discovery with Cutting-Edge Technology A SeNostic Company Presentation SeNostic aims to enhance
Read moreSeNostic is Revolutionising Neurodegenerative Disease Detection and Drug Discovery with Cutting-Edge Technology A SeNostic Company Presentation SeNostic aims to enhance
Read moreAbbVie has reported positive topline results from its pivotal Phase 3 TEMPO-1 trial evaluating tavapadon as a monotherapy for early-stage
Read moreGroundbreaking Research Highlights ipRGCs as Promising Biomarkers for Neurodegenerative Diseases A Striatech .pdf Case Study OptoDrum plays a key role
Read moreParkinson’s disease (PD) is a progressive neurodegenerative condition impacting millions globally. While a blend of genetic, environmental, and ageing factors
Read moreVentus Therapeutics, a US-based clinical-stage biopharmaceutical company leveraging its exclusive structural biology and computational chemistry platform, ReSOLVE™, has disclosed promising
Read moreAbbVie has introduced PRODUODOPA® (foslevodopa/foscarbidopa) in the European Union to address advanced Parkinson’s disease. AbbVie (NYSE: ABBV) recently announced the
Read moreAlzheimer’s disease (AD) and Parkinson’s disease (PD) stand as the two most prevalent neurodegenerative disorders, each characterized by the cerebral
Read moreStressMarq Biosciences, a pioneer in the development and commercialization of unique fibrilized and oligomeric protein preparations to propel the study
Read moreA collaboration between StressMarq Biosciences and Gubra has generated a 3D whole-brain light sheet fluorescence imaging model depicting alpha-synuclein pSer129+
Read moreStressMarq manufactures and offers a wide range of products specifically developed to accelerate Parkinson’s disease research. StressMarq’s cutting-edge product range
Read more